Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients

Critical Care

Volumn 18, Issue 4, 2014, Pages

  Darcy, Christabelle J ^a   Minigo, Gabriela ^a   Piera, Kim A ^a   Davis, Joshua S ^a,b   McNeil, Yvette R ^a   Chen, Youwei ^c   Volkheimer, Alicia D ^c   Weinberg, J Brice ^c   Anstey, Nicholas M ^a,b   Woodberry, Tonia ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; CD11B ANTIGEN; CD15 ANTIGEN; CD3 ANTIGEN; FICOLL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR; CYTOKINE;

ADULT; ARTICLE; AUSTRALIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERPHASE; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEPTIC SHOCK; SUPPRESSOR CELL; TERTIARY CARE CENTER; APACHE; BLOOD; BONE MARROW CELL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; ORGAN DYSFUNCTION SCORE; PATHOPHYSIOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE;

ADULT; APACHE; ARGINASE; ARGININE; AUSTRALIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; NEUTROPHILS; ORGAN DYSFUNCTION SCORES; RNA, MESSENGER; SHOCK, SEPTIC; STATISTICS, NONPARAMETRIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T-LYMPHOCYTES;

EID: 84907420706     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc14003     Document Type: Article

References (57)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004, 30:589-596.
4. Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, Collado J, Garcia-Labattut A, Carriedo D, Valledor M, De Frutos M, López MJ, Caballero A, Guerra J, Alvarez B, Mayo A, Villar J,. Grupo de Estudios y Análisis en Cuidados Intensivos Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 2008, 12:R158. Grupo de Estudios y Análisis en Cuidados Intensivos.
5. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, 15:496-497.
6. Lyn-Kew K, Standiford TJ. Immunosuppression in sepsis. Curr Pharm Des 2008, 14:1870-1881.
7. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis 2001, 1:165-174.
8. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
9. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997, 25:1095-1100.
10. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984, 311:1137-1143.
11. MacLean LD, Meakins JL, Taguchi K, Duignan JP, Dhillon KS, Gordon J. Host resistance in sepsis and trauma. Ann Surg 1975, 182:207-217.
12. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998, 26:1076-1082.
13. von Muller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N, Hampl W, Mertens T. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 2006, 12:1517-1522.
14. Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, Siewert JR, Holzmann B. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 1999, 178:288-292.
15. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drenou B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18:487-494.
16. Christou NV, Meakins JL, Gordon J, Yee J, Hassan-Zahraee M, Nohr CW, Shizgal HM, MacLean LD. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 1995, 222:534-546.
17. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78.
18. Davis JS, Anstey NM. Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med 2011, 39:380-385.
19. Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park HJ, Lan MS, Zea AH, Ochoa AC. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res 2001, 7:958s-965s.
20. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
21. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003, 171:1232-1239.
22. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, Ho AD. Suppression of T-cell functions by human granulocyte arginase. Blood 2006, 108:1627-1634.
23. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012, 144:250-268.
24. Bryk JA, Popovic PJ, Zenati MS, Munera V, Pribis JP, Ochoa JB. Nature of myeloid cells expressing arginase 1 in peripheral blood after trauma. J Trauma 2010, 68:843-852.
25. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH, Leenen LP, Pickkers P, Koenderman L. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012, 122:327-336.
26. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204:1463-1474.
27. Kong YY, Fuchsberger M, Xiang SD, Apostolopoulos V, Plebanski M. Myeloid derived suppressor cells and their role in diseases. Curr Med Chem 2013, 20:1437-1444.
28. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
29. Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012, 61:827-838.
30. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
31. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
32. van den Akker EL, Baan CC, van den Berg B, Russcher H, Joosten K, Hokken-Koelega AC, Lamberts SW, Koper JW. Ficoll-separated mononuclear cells from sepsis patients are contaminated with granulocytes. Intensive Care Med 2008, 34:912-916.
33. Lazarus AH, Ellis J, Blanchette V, Freedman J, Sheng-Tanner X. Permeabilization and fixation conditions for intracellular flow cytometric detection of the T-cell receptor zeta chain and other intracellular proteins in lymphocyte subpopulations. Cytometry 1998, 32:206-213.
34. Roche Universal Probe Library Assay Design Center. [http://universalprobelibrary.com/].
35. Wang H, McNeil YR, Yeo TW, Anstey NM. Simultaneous determination of multiple amino acids in plasma in critical illness by high performance liquid chromatography with ultraviolet and fluorescence detection. J Chromatogr B 2013, 940:53-58.
36. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294:81-90.
37. Davis JS, Yeo TW, Thomas JH, McMillan M, Darcy CJ, McNeil YR, Cheng AC, Celermajer DS, Stephens DP, Anstey NM. Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study. Crit Care 2009, 13:R155.
38. Elghetany MT. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 2002, 28:260-274.
39. Tacke RS, Lee HC, Goh C, Courtney J, Polyak SJ, Rosen HR, Hahn YS. Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology 2012, 55:343-353.
40. Garg A, Spector SA. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis 2014, 209:441-451.
41. Rieber N, Brand A, Hector A, Graepler-Mainka U, Ost M, Schafer I, Wecker I, Neri D, Wirth A, Mays L, Zundel S, Fuchs J, Handgretinger R, Stern M, Hogardt M, Döring G, Riethmüller J, Kormann M, Hartl D. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 2013, 190:1276-1284.
42. De Santo C, Salio M, Masri SH, Lee LY, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, Gröne HJ, Platt FM, Zambon M, Cerundolo V. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008, 118:4036-4048.
43. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Muller M, Blander JM, Tacke F, Trautwein C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010, 207:1453-1464.
44. Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: when enough is too much. J Pathol 2013, 231:8-20.
45. Giamarellos-Bourboulis EJ. What is the pathophysiology of the septic host upon admission?. Int J Antimicrob Agents 2010, 36:S2-S5.
46. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
47. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, Bukowski RM, Ochoa AC. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993, 53:5613-5616.
48. Gunji Y, Hori S, Aoe T, Asano T, Ochiai T, Isono K, Saito T. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 1994, 85:1189-1192.
49. Matsuda M, Ulfgren AK, Lenkei R, Petersson M, Ochoa AC, Lindblad S, Andersson P, Klareskog L, Kiessling R. Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol 1998, 47:254-262.
50. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998, 101:1448-1457.
51. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4:675-687.
52. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
53. Goddard DS, Yamanaka K, Kupper TS, Jones DA. Activation of neutrophils in cutaneous T-cell lymphoma. Clin Cancer Res 2005, 11:8243-8249.
54. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010, 185:2273-2284.
55. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
56. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006, 368:157-169.
57. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Signal extinction and T cell repolarization in T helper cell-antigen-presenting cell conjugates. Eur J Immunol 1996, 26:2012-2016.